Fox Run Management L.L.C. Buys 7,654 Shares of Zoetis Inc. (NYSE:ZTS)

Fox Run Management L.L.C. raised its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 512.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,148 shares of the company's stock after acquiring an additional 7,654 shares during the quarter. Fox Run Management L.L.C.'s holdings in Zoetis were worth $1,490,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of ZTS. Atlantic Edge Private Wealth Management LLC grew its holdings in Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 140 shares during the period. Rakuten Securities Inc. increased its holdings in Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after acquiring an additional 166 shares in the last quarter. Darwin Wealth Management LLC bought a new stake in Zoetis during the 3rd quarter worth approximately $31,000. Dunhill Financial LLC lifted its holdings in Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company's stock valued at $33,000 after purchasing an additional 75 shares in the last quarter. Finally, Asset Planning Inc bought a new position in shares of Zoetis in the fourth quarter worth approximately $58,000. Institutional investors own 92.80% of the company's stock.

Zoetis Trading Down 0.8 %

Shares of ZTS stock traded down $1.29 on Tuesday, reaching $161.89. 512,934 shares of the company's stock were exchanged, compared to its average volume of 2,499,127. The company's fifty day simple moving average is $166.70 and its 200 day simple moving average is $175.22. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.33. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The stock has a market capitalization of $72.49 billion, a PE ratio of 29.59, a P/E/G ratio of 2.78 and a beta of 0.94.

Remove Ads

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. As a group, analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.24%. Zoetis's payout ratio is 36.56%.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Barclays raised their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research report on Friday, February 14th. Piper Sandler upped their target price on shares of Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Leerink Partnrs upgraded shares of Zoetis to a "strong-buy" rating in a research note on Monday, December 2nd. UBS Group started coverage on shares of Zoetis in a report on Monday, December 9th. They set a "neutral" rating and a $196.00 price objective for the company. Finally, Leerink Partners assumed coverage on Zoetis in a report on Monday, December 2nd. They issued an "outperform" rating and a $215.00 target price on the stock. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $215.90.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares of the company's stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares of the company's stock, valued at $1,868,244.30. The trade was a 9.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,862 shares of company stock valued at $312,254 over the last quarter. 0.16% of the stock is owned by corporate insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.